Vericiguat, the first sGC stimulator approved for HFrEF, has demonstrated clinical efficacy in reducing cardiovascular death and heart failure-related hospitalizations, particularly in patients with recent decompensation [3,4,5]. The gene discussed is SGCB; the disease is heart failure.